Cell Migration Assay Details
ORIS Assay Description
The ORIS assay is well suited for the testing of compounds that inhibit undirected tumor cell migration. It is performed in a 96 well format and can be used for screening with medium throughput rates with high accuracy.
Assay procedure. (A) Tumor cells are seeded onto collagen I-coated multi-well plates equipped with a barrier that prevents cell adherence to the center of each well. After 18 hours, the barrier is removed (B) revealing a clear region in the center of the well. During a 24- to 48-hour incubation period in the presence of test compound (C), tumor cells migrate into this detection zone (D) which is monitored by fluorescent-labeled cells (E).
The assay is performed with the ORIS assay kit from Platypus.
ORIS Assay Example Data
ORIS Assay example data. A c-Src inhibitor was incubated with breast cancer cells for 48 hours, and the migration of cells into the detection zone was visualized by fluorescence photography (left), and results presented as a dose-response curve (right). Negative control = solvent; positive control = removal of the cell barrier at the end of the test compound incubation.
ORIS Assay Details
Setup: IC50 value determination. Drug combination testing is possible.
Controls: Removal of stoppers at the endpoint is the low control. DMSO only treatment is the high control. Reference control treatment is performed for quality control in every project.
Custom-tailored assays can be performed. This assay can be established with new cell lines according to the client’s research needs.
Turnaround time: Around 3 weeks. Expedited scheduling and data delivery can be arranged prior to study commencement.
Report: A detailed report including assay conditions, methodology, and comprehensive evaluation of data as well as raw data for own analysis will be provided. Photographs of colonies can be provided upon request.
Screening facility: The assay is performed in Freiburg, Germany.
Compound requirements: In brief, please provide at least 30 μl of a 1000x stock solution of the highest testing concentration in DMSO or the equivalent of solid powder.
Wound Healing Assay Description
The Wound Healing Assay (or Scratch Assay) measures the impact of compounds on undirected cell migration after wound-making via scratching the cell monolayer. The assay is suitable for investigation of tumor and normal cells and is performed with IncuCyte system which enables real-time monitoring of cell migration.
Assay procedure. (A) Tumor cells grow to monolayers. (B) Using the WoundMaker, homogeneous scratches will be created mechanically with pins in a 96 well format. (C) After the application of the test compound, plates incubate in the IncuCyte S3 instrument for real-time quantification of tumor cells migrating into the scratch zone (D).
Wound Healing Assay Example Data
Effect of inhibition of cell migration on HT-1080 cells. HT-1080 cells with red fluorescence were seeded into ImageLock plates in complete growth media. After the cells reached about 90% confluence, wounds in all wells were simultaneously created using the WoundMaker tool. Cytochalasin D was added at serial dilutions and plates were placed in the IncuCyte instrument for scheduled scanning.
Upper left: Time course of the effect of an inhibitor of actin polymerization on wound healing over 24-hours. Upper right: Dose-dependent effect of the drug on wound healing at 8h time point. Lower panel: Representative images of wound healing at 8h time point. The blue areas represent the initial wound scratches.
Wound Healing Assay Details
Setup: IC50 value determination with 10 concentrations in triplicates performed in 96 well format. Drug combination testing is possible.
Controls: DMSO only control serves as high control. A reference compound recommended by the client is used for positive control.
Assay development: Custom-tailored assays can be performed. This assay can be established with new cell lines according to the client’s research needs.
Turnaround time: Around 3 weeks.
Report: Raw data, IC50 curves, and IC50 values as well as representative images of wound closure are provided in the report.
Screening facility: The assay is performed in Malvern, US.
Compound requirements: In brief, please provide 20-50 μl of 10-50 mM DMSO stock or the equivalent of solid powder. Please refer to our FAQs for information regarding compound preparation and shipping.